Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes

Published on 04 Jun 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Finerenone 10 mg and 20 mg tablets as an add-on therapy for adults with chronic kidney disease and albuminuria associated with type 2 diabetes:

  • who are receiving concomitant optimal standard treatment which includes an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) at maximum tolerated dose in combination with a sodium-glucose co-transporter 2 (SGLT2) inhibitor, unless contraindicated or not tolerated, and

  • who have estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73m2 and urine albumin-to-creatinine ratio (UACR) ≥200 mg/g (20 mg/mmol) at the start of treatment.

Funding Status

Finerenone 10 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.

Finerenone must be initiated by, or in consultation with, a specialist physician experienced in the management of chronic kidney disease and albuminuria associated with type 2 diabetes.

Treatment with finerenone must be discontinued prior to initiating dialysis.

Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes (Updated 16 Sep 2025)

PES_Finerenone for treating chronic kidney disease and protein in the urine associated with type 2 diabetes (Updated 16 Sep 2025)